Tegavivint and the β-catenin/ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of the National Cancer Institute"
DOI: 10.1093/jnci/djz026
Abstract: BACKGROUND The Wnt/β-catenin pathway is closely associated with osteosarcoma (OS) development and metastatic progression. We investigated the antitumor activity of Tegavivint, a novel β-catenin/transducing β-like protein 1 (TBL1) inhibitor, against OS employing in vitro, ex… read more here.
Keywords: vivo; catenin; group; pdx ... See more keywords
Abstract 4533: Serum protein changes in patients with desmoid tumors responsive to the TBL1 inhibitor, tegavivint
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-4533
Abstract: Background: A Phase 1/2 clinical trial (NCT03459469) of the small molecule tegavivint in patients with desmoid tumors (DTs), demonstrated drug safety and tolerability with evidence of clinical activity. Transducin Beta-Like Protein 1 (TBL1) is a… read more here.
Keywords: beta catenin; serum; tegavivint; desmoid tumors ... See more keywords
Combination of Histone Deacetylase Inhibitor Panobinostat (LBH589) with β-Catenin Inhibitor Tegavivint (BC2059) Exerts Significant Anti-Myeloma Activity Both In Vitro and In Vivo
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14030840
Abstract: Simple Summary Multiple myeloma remains an incurable malignancy with the majority of patients succumbing to the disease after receiving several lines of treatment, while acquiring drug resistance. Although panobinostat, a histone deacetylase inhibitor, has long… read more here.
Keywords: catenin; vivo; myeloma; tegavivint ... See more keywords